1 / 9

New development in ME – M yalgic Encephalomyelitis in Norway

New development in ME – M yalgic Encephalomyelitis in Norway. Marianne Bjærum Christine Normann. What is ME?. Temporary unknown cause Officially called “Chronic Fatigue Syndrome” F irst classified into the International Classification of Diseases in 1969

harley
Download Presentation

New development in ME – M yalgic Encephalomyelitis in Norway

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New development in ME – Myalgic Encephalomyelitisin Norway Marianne Bjærum Christine Normann

  2. What is ME? • Temporary unknown cause • Officially called “Chronic Fatigue Syndrome” • First classified into the International Classification of Diseases in 1969 • In Norway alone it is estimated that 15.000 people have ME – predominantly women • No test exist, therefore excluding other diseases is important for diagnosis

  3. Symptoms • Impaired memory and cognitive complaints • Sore throat • Tender cervical or axillary lymph nodes • Muscle pain • Multi-joint pain • New headaches • Un-refreshing sleep • Post-exertional malaise lasting more than 24 hours

  4. New research • A study published in 2009 in “Science” reported an association between ME and a retrovirus • In September 2011, the authors published a "Partial Retraction" of their 2009 findings

  5. New research • October 2011, A Study at Haukeland University hospital, Bergen, Norway • Cancer treatment improved patients CFS conditions • Randomised, double-blind study, 30 patients • 2 out of 3 patients with improved condition

  6. Rituximab • Achimeric monoclonal antibody that attacks the B-lymphocytes • Used in the treatment of many lymphomas, leukemias and some autoimmune disorders • Destroys both normal and malignant B-ly that have CD20 on their surfaces • Therefore used to treat diseases which are characterized by having too many B-ly, overactive B-ly or dysfunctional B-ly

  7. Theories • Autoimmune disease • Abig subgroup of these patients have a autoimmune disease maintaining itself by a autoantibody. • The B-lymphocytes act as a reservoir for a virus with a big impact on this disease.

  8. Newly released • Research article: Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study • New book released in October in Norway – historically, politically, national and international, and how to live with ME

  9. Resources • http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0026358 • http://www.me-foreningen.no/ • http://en.wikipedia.org/wiki/Chronic_fatigue_syndrome • http://www.cfids.org/community/pcpep/curriculum.asp

More Related